Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

NCT05935085 is registered in ClinicalTrials.gov with AnaptysBio, Inc. as lead sponsor.

NCT NCT05935085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05935085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
Lead sponsor
AnaptysBio, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 13, 2023
Completion date
January 7, 2025
Enrollment
201 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis eczema